首页> 外文期刊>Acta histochemica et cytochemica >Pathological Evaluation of HER2 Overexpression:For the Treatment of Metastatic Breast Cancers by Humanized Anti-HER2 Monoclonal Antibody (Trastuzumab)
【24h】

Pathological Evaluation of HER2 Overexpression:For the Treatment of Metastatic Breast Cancers by Humanized Anti-HER2 Monoclonal Antibody (Trastuzumab)

机译:HER2过表达的病理评估:用于人源化抗HER2单克隆抗体(曲妥珠单抗)治疗转移性乳腺癌

获取原文
获取原文并翻译 | 示例
           

摘要

For the treatment of patients with meta-static breast cancer by humanized anti-human epidermal growth factor receptor type 2 (HER2) antibody (trastuzumab), it is important to evaluate HER2 status adequately. This article overviews developments of basic and clinical research for HER2 gene, and introduces general agreement with the evaluation system of HER2 overexpression with several commentaries from the aspect of histochem-istry.
机译:对于通过人源化抗人表皮生长因子受体2(HER2)抗体(曲妥珠单抗)治疗转移性乳腺癌患者,重要的是充分评估HER2的状态。本文概述了HER2基因的基础和临床研究的进展,并从组织化学方面介绍了与HER2过表达评估系统的总体一致性,并作了一些评论。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号